SANANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Sana Biotechnology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$2.30+0.03 (+1.32%)
Close on Oct 19, 2026
- Market cap
- $680.03M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 101.2% | -118.7% | |
| Return on assets | – | – | -53.2% | |
| Current ratio | – | 12.22 | 1.89 | |
| Diluted shares | – | 13M | 253M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Sana Biotechnology generated $1.16B from operations and spent $105.14M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$1.16B
Used
$105.14M
Capital expenditure$105.14M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$244.17M
- Cash generatingOperating cash flow above zero-$143.83M
- Return on assets improvedROA up on the prior year-47.2% → -48.7%
- Earnings backed by cashOperating cash flow above net income-$143.83M vs -$244.17M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose3.54 → 1.89
- No dilutionShare count did not rise231M → 253M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –